Literature DB >> 15307870

Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera.

Dana L Bruden1, Brian J McMahon, Thomas W Hennessy, Carol J Christensen, Chriss E Homan, James L Williams, Daniel G Sullivan, David R Gretch, Henry H Cagle, Lisa R Bulkow.   

Abstract

OBJECTIVES: Studies on the natural history and outcome of chronic hepatitis C virus (HCV) infection differ regarding the proportion of persons who develop serious sequelae over time. Most of these studies use an estimated date of HCV infection based on risk factor data obtained from patient interviews. The date of HCV infection is often estimated using the year of a pre-1992 blood transfusion (BT), or the first year of injecting drug use (IDU). We sought to determine the accuracy of these dates obtained by interview.
METHODS: We compared BT dates reported by patients in a long-term HCV outcome study to dates confirmed in a BT-Lookback project, and also compared the reported first year of IDU to seroconversion dates estimated from HCV tests on historical sera.
RESULTS: Of 28 BT recipients who were interviewed in the HCV outcome study and identified in the Lookback project, 14 (50%; 95% CI: 31-69%) were unaware they had received a BT. Of 25 persons identified in the BT-Lookback project with historical sera available, 9 (36%; 95% CI: 19-57%) had anti-HCV results that did not correlate with their confirmed BT date. Of 216 persons with a history of IDU and historical serum samples available, 66 (31%; 95% CI: 25-37%) had anti-HCV results that did not correlate with their reported first year of IDU.
CONCLUSIONS: Inaccuracies in the length of HCV could occur in outcome studies that rely on patient recall of risk-factor history. Statistical methods that incorporate the uncertainty in assigning infection date are needed. Copyright 2004 American College of Gastroenterology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307870     DOI: 10.1111/j.1572-0241.2004.30826.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.

Authors:  Dana J T Bruden; Brian J McMahon; Lisa Townshend-Bulson; Prabhu Gounder; Jim Gove; Julia Plotnik; Chriss Homan; Annette Hewitt; Youssef Barbour; Philip R Spradling; Brenna C Simons; Susan McArdle; Michael Bruce
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

2.  Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C.

Authors:  Stephen E Livingston; Heike Deubner; Dana L Bruden; Brian J McMahon; Chriss E Homan; Lisa J Townshend-Bulson; Michael G Bruce; Thomas W Hennessy; James L Williams; David R Gretch
Journal:  Can J Gastroenterol       Date:  2010-07       Impact factor: 3.522

3.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

4.  Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.

Authors:  Mehdi Assmar; Sara Yeganeh; Fariborz Mansourghanaei; Nour Amirmozafari
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

5.  Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection.

Authors:  Timothy J Stevenson; Youssef Barbour; Brian J McMahon; Lisa Townshend-Bulson; Annette M Hewitt; Hannah G F Espera; Chriss Homan; Peter Holck; Sarah V Luna; Cindy Knall; Brenna C Simons
Journal:  Open Forum Infect Dis       Date:  2019-05-17       Impact factor: 3.835

6.  The Alaska Area Specimen Bank: a tribal-federal partnership to maintain and manage a resource for health research.

Authors:  Alan J Parkinson; Thomas Hennessy; Lisa Bulkow; H Sally Smith
Journal:  Int J Circumpolar Health       Date:  2013-04-16       Impact factor: 1.228

7.  Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.

Authors:  Stephen E Livingston; Lisa J Townshend-Bulson; Dana J T Bruden; Chriss E Homan; James E Gove; Julia N Plotnik; Brenna C Simons; Philip R Spradling; Brian J McMahon
Journal:  Int J Circumpolar Health       Date:  2016-03-29       Impact factor: 1.228

8.  Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.

Authors:  Aysegul Erman; Murray D Krahn; Tawnya Hansen; Josephine Wong; Joanna M Bielecki; Jordan J Feld; William W L Wong; Paul Grootendorst; Hla-Hla Thein
Journal:  BMJ Open       Date:  2019-11-11       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.